Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

A Single Center Study of the Safety and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects With CNV Secondary to Causes Other Than AMD.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00395551

Enrollment

Registered

2006-11-03

Start date

2005-12-31

Completion date

2009-06-30

Last updated

2010-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal Neovascularization

Keywords

choroidal neovascularization, Choroidal Neovascularization Not related to Age-Related Macular Degeneration

Brief summary

The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.

Interventions

DRUGranibizumab

0.5mg intravitreal injection

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* active choroidal neovascularization

Exclusion criteria

* pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies

Design outcomes

Primary

Measure	Time frame
The primary outcome measures for safety and tolerability	Mean change in visual acuity from baseline to 6 months & 12 months

Secondary

Measure	Time frame
The secondary outcome measures for efficacy	Mean change in visual acuity from baseline to 6 & 12 months. Change in retinal thickness from baseline to week 1, month 1, 2, 3, 6, & 12 measured by OCT. Change in area of CNV from baseline to month 3, 6 & 12 measured by FA

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026